The Truth About Compounded GLP-1 Medications

Yes, when done correctly. Federal law allows pharmacies to compound medications when there is a drug shortage or when a patient needs a clinically significant difference (like a different salt form, dosage, or delivery method). As of November 2025, compounding remains legal but providers must create formulations that differ meaningfully from brand-name products.

It depends entirely on the pharmacy. Compounded medications are not FDA-approved, meaning they haven't undergone the same rigorous testing. However, pharmacies that follow cGMP standards, use FDA-registered 503b facilities, and provide third-party testing can produce high-quality medications. The FDA has found potency variations ranging from 42-170% in some compounded GLP-1 products, which is why choosing a certified provider is critical.

Brand-name Wegovy typically costs $1,000-1,400 per month without insurance. Compounded semaglutide ranges from $200-400 per month, including consultation fees. The wide price range reflects different pharmacy types, included services, and quality standards. Lower prices may indicate corners being cut on testing or quality control.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, meaning it targets two pathways instead of one. Clinical trials show tirzepatide typically produces greater weight loss (15-22.5% vs 10-15%), but it may also have more gastrointestinal side effects. Both are available in compounded form.

Yes, if you have a prescription and meet BMI requirements (typically BMI ≥30 or BMI ≥27 with weight-related conditions). HSA/FSA funds can be used for prescription weight loss medications. Check with your specific provider to confirm they process HSA/FSA payments.

Common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose increases. These typically improve over time. Contact your prescribing provider immediately if you experience severe abdominal pain, vision changes, or signs of pancreatitis. You can also report adverse events to the FDA via MedWatch.